Clinical trial
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic…
NCT00459654 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00459654 |
|---|---|
| Title | A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer |
| Official title | A Phase II Randomised, Placebo-controlled, Multicentre Study in Prostate Cancer Patients With Painful Bone Metastases to Evaluate the Efficacy of Repeated Radium-223 Injections |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Radium-223 dichloride (BAY88-8223), Saline |
| Enrollment | 64 |
| Start date | Feb 1, 2004 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Apr 12, 2007 |
| Last update posted | Jun 25, 2014 |
| Countries | Sweden, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: